Elamipretide (SS-31)
Fat LossFDA-approved mitochondria-targeted tetrapeptideEstablished
Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required.
For research use only.
Key Facts
- CAS
- 93479-97-1
- Molecular Weight (MW)
- 627.8 g/mol
- Half-life
- ~4–5 h (iv) in human studies
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- 8/23/2026
- Targets
- CardiolipinInner mitochondrial membrane
Overview
Mitochondria-targeted tetrapeptide. FDA granted accelerated approval in September 2025 to Forzinity (elamipretide) to improve muscle strength in Barth syndrome patients ≥30 kg. Confirmatory trial required.
Protocol
- Dosage Range
- 40 mg once daily (Forzinity labeled dose, patients ≥30 kg)
- Frequency
- Once daily
- Cycle
- Chronic labeled use under specialist care
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Use approved Forzinity presentation per label
Science
Mechanism of Action
Binds cardiolipin on the inner mitochondrial membrane, improving cristae structure and electron-transport efficiency and reducing ROS in dysfunctional mitochondria.
Targets
CardiolipinInner mitochondrial membrane
Studies
- TAZPOWER / Barth syndrome elamipretide program— Journal/year not available
- SS-31 mitochondrial peptide mechanism— Journal/year not available
Benefits
Labeled Barth syndrome muscle-strength indicationMitochondrial-structure research
Potential Side Effects
- Injection-site reactions
- Eosinophilia reported in development
- Headache
References
- FDA accelerated approval — ForzinityExternal link · Year —
- DailyMed — ForzinityExternal link · Year —
- PMID 18481172External link · Year —